$24.00
0.15[0.63%]
Last update: 4:10PM Get Real Time Here
Mirum Pharmaceuticals
(NASDAQ:MIRM)Mirum Pharmaceuticals Stock (NASDAQ:MIRM), Analyst Ratings, Price Targets, Predictions
Mirum Pharmaceuticals Inc has a consensus price target of $50.58, established from looking at the 61 latest analyst ratings. The last 3 analyst ratings were released from Stifel, HC Wainwright & Co., and Leerink Partners on April 17, 2024, April 2, 2024, and March 18, 2024. With an average price target of $49.67 between Stifel, HC Wainwright & Co., and Leerink Partners, there's an implied 110.81% upside for Mirum Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Stifel
HC Wainwright & Co.
Leerink Partners
JMP Securities
Cantor Fitzgerald
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Mirum Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/17/2024 | MIRM | Buy Now | Mirum Pharmaceuticals | $23.56 | 103.74% | Stifel | Dae Gon Ha | → $48 | Initiates | → Buy | Get Alert |
| 04/02/2024 | MIRM | Buy Now | Mirum Pharmaceuticals | $23.56 | 146.18% | HC Wainwright & Co. | Ed Arce | $58 → $58 | Maintains | Buy | Get Alert |
| 03/18/2024 | MIRM | Buy Now | Mirum Pharmaceuticals | $23.56 | 82.51% | Leerink Partners | Mani Foroohar | $44 → $43 | Maintains | Outperform | Get Alert |
| 03/14/2024 | MIRM | Buy Now | Mirum Pharmaceuticals | $23.56 | 205.6% | JMP Securities | Jonathan Wolleben | $69 → $72 | Maintains | Outperform | Get Alert |
| 03/14/2024 | MIRM | Buy Now | Mirum Pharmaceuticals | $23.56 | 146.18% | HC Wainwright & Co. | Ed Arce | $45 → $58 | Maintains | Buy | Get Alert |
| 03/04/2024 | MIRM | Buy Now | Mirum Pharmaceuticals | $23.56 | 69.78% | Cantor Fitzgerald | Josh Schimmer | $35 → $40 | Maintains | Overweight | Get Alert |
| 02/29/2024 | MIRM | Buy Now | Mirum Pharmaceuticals | $23.56 | 91% | HC Wainwright & Co. | Ed Arce | $58 → $45 | Maintains | Buy | Get Alert |
| 02/29/2024 | MIRM | Buy Now | Mirum Pharmaceuticals | $23.56 | 192.87% | JMP Securities | Jonathan Wolleben | $64 → $69 | Maintains | Market Outperform | Get Alert |
| 02/29/2024 | MIRM | Buy Now | Mirum Pharmaceuticals | $23.56 | 48.56% | Cantor Fitzgerald | Josh Schimmer | → $35 | Reiterates | Overweight → Overweight | Get Alert |
| 01/11/2024 | MIRM | Buy Now | Mirum Pharmaceuticals | $23.56 | 171.65% | JMP Securities | Jonathan Wolleben | → $64 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 12/19/2023 | MIRM | Buy Now | Mirum Pharmaceuticals | $23.56 | 171.65% | Raymond James | Steven Seedhouse | $78 → $64 | Maintains | Strong Buy | Get Alert |
| 12/18/2023 | MIRM | Buy Now | Mirum Pharmaceuticals | $23.56 | 146.18% | HC Wainwright & Co. | Ed Arce | $60 → $58 | Maintains | Buy | Get Alert |
| 11/27/2023 | MIRM | Buy Now | Mirum Pharmaceuticals | $23.56 | 112.22% | Cantor Fitzgerald | Josh Schimmer | → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 11/20/2023 | MIRM | Buy Now | Mirum Pharmaceuticals | $23.56 | 57.05% | JP Morgan | Jessica Fye | → $37 | Reinstates | → Overweight | Get Alert |
| 11/15/2023 | MIRM | Buy Now | Mirum Pharmaceuticals | $23.56 | 112.22% | Cantor Fitzgerald | Joshua Schimmer | → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 11/13/2023 | MIRM | Buy Now | Mirum Pharmaceuticals | $23.56 | 154.67% | Morgan Stanley | Michael Ulz | → $60 | Initiates | → Overweight | Get Alert |
| 11/03/2023 | MIRM | Buy Now | Mirum Pharmaceuticals | $23.56 | 154.67% | HC Wainwright & Co. | Ed Arce | $63 → $60 | Maintains | Buy | Get Alert |
| 10/24/2023 | MIRM | Buy Now | Mirum Pharmaceuticals | $23.56 | 112.22% | Cantor Fitzgerald | Joshua Schimmer | → $50 | Initiates | → Overweight | Get Alert |
| 10/18/2023 | MIRM | Buy Now | Mirum Pharmaceuticals | $23.56 | 197.11% | JMP Securities | Jonathan Wolleben | → $70 | Reiterates | Market Outperform → Market Outperform | Get Alert |
FAQ
What is the target price for Mirum Pharmaceuticals (MIRM)?
The latest price target for Mirum Pharmaceuticals (NASDAQ: MIRM) was reported by Stifel on April 17, 2024. The analyst firm set a price target for $48.00 expecting MIRM to rise to within 12 months (a possible 100.00% upside). 32 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Mirum Pharmaceuticals (MIRM)?
The latest analyst rating for Mirum Pharmaceuticals (NASDAQ: MIRM) was provided by Stifel, and Mirum Pharmaceuticals initiated their buy rating.
When was the last upgrade for Mirum Pharmaceuticals (MIRM)?
There is no last upgrade for Mirum Pharmaceuticals.
When was the last downgrade for Mirum Pharmaceuticals (MIRM)?
There is no last downgrade for Mirum Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Mirum Pharmaceuticals (MIRM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mirum Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mirum Pharmaceuticals was filed on April 17, 2024 so you should expect the next rating to be made available sometime around April 17, 2025.
Is the Analyst Rating Mirum Pharmaceuticals (MIRM) correct?
While ratings are subjective and will change, the latest Mirum Pharmaceuticals (MIRM) rating was a initiated with a price target of $0.00 to $48.00. The current price Mirum Pharmaceuticals (MIRM) is trading at is $24.00, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.